William John Samson

William John Samson

Auto-generated profile, based on publicly available information

William John Samson

Biomedical Biotechnology Research Unit (BioBRU), Department of Biochemistry and Microbiology, Rhodes University, Grahamstown, 6140, South Africa

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KDKarim Colin Hassan Dhanani
Karim Colin Hassan Dhanani
WSWilliam John Samson
William John Samson
Adrienne Lesley EdkinsAdrienne Lesley Edkins
Adrienne Lesley Edkins
Fibronectin is an extracellular matrix glycoprotein with key roles in cell adhesion and migration. Hsp90 binds directly to fibronectin and Hsp90 depletion regulates fibronectin matrix stability. Where inhibition of Hsp90 with a C-terminal inhibitor, novobiocin, reduced the fibronectin matrix, treatment with an N-terminal inhibitor, geldanamycin, increased fibronectin levels. Geldanamycin treatment induced a stress response and a strong dose and time dependent increase in fibronectin mRNA via activation of the fibronectin promoter. Three putative heat shock elements (HSEs) were identified in the fibronectin promoter. Loss of two of these HSEs reduced both basal and geldanamycin-induced promoter activity, as did inhibition of the stress-responsive transcription factor HSF1. Binding of HSF1 to one of the putative HSE was confirmed by ChIP under basal conditions, and occupancy shown to increase with geldanamycin treatment. These data support the hypothesis that fibronectin is stress-responsive and a functional HSF1 target gene. COLA42 and LAMB3 mRNA levels were also increased with geldanamycin indicating that regulation of extracellular matrix (ECM) genes by HSF1 may be a wider phenomenon. Taken together, these data have implications for our understanding of ECM dynamics in stress-related diseases in which HSF1 is activated, and where the clinical application of N-terminal Hsp90 inhibitors is intended.

1 June 2019 in Inorganica Chimica Acta
Verified
Journal Article
Closed access
LGLarusha Gramni
Larusha Gramni
NVNyeleti Vukea
Nyeleti Vukea
Abir ChakrabortyAbir Chakraborty
Abir Chakraborty
WSWilliam John Samson
William John Samson
LDLaura Margaret Kirkpartick Dingle
Laura Margaret Kirkpartick Dingle
IBIrvin Noel Booysen
Irvin Noel Booysen